Long-term survival analysis of masitinib in amyotrophic lateral sclerosis.

Background:A randomized, placebo-controlled phase III study (AB10015) previously demonstrated that orally administered masitinib (4.5 mg/kg/day) slowed rate of functional decline, with acceptable s...